Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 9/2013

01.09.2013 | Original Article

Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer’s disease dementia

verfasst von: Javier Arbizu, E. Prieto, P. Martínez-Lage, J. M. Martí-Climent, M. García-Granero, I. Lamet, P. Pastor, M. Riverol, M. T. Gómez-Isla, I. Peñuelas, J. A. Richter, M. W. Weiner, for the Alzheimer’s Disease Neuroimaging Initiative

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To introduce, evaluate and validate a voxel-based analysis method of 18F-FDG PET imaging for determining the probability of Alzheimer’s disease (AD) in a particular individual.

Methods

The subject groups for model derivation comprised 80 healthy subjects (HS), 36 patients with mild cognitive impairment (MCI) who converted to AD dementia within 18 months, 85 non-converter MCI patients who did not convert within 24 months, and 67 AD dementia patients with baseline FDG PET scan were recruited from the AD Neuroimaging Initiative (ADNI) database. Additionally, baseline FDG PET scans from 20 HS, 27 MCI and 21 AD dementia patients from our institutional cohort were included for model validation. The analysis technique was designed on the basis of the AD-related hypometabolic convergence index adapted for our laboratory-specific context (AD-PET index), and combined in a multivariable model with age and gender for AD dementia detection (AD score). A logistic regression analysis of different cortical PET indexes and clinical variables was applied to search for relevant predictive factors to include in the multivariable model for the prediction of MCI conversion to AD dementia (AD-Conv score). The resultant scores were stratified into sixtiles for probabilistic diagnosis.

Results

The area under the receiver operating characteristic curve (AUC) for the AD score detecting AD dementia in the ADNI database was 0.879, and the observed probability of AD dementia in the six defined groups ranged from 8 % to 100 % in a monotonic trend. For predicting MCI conversion to AD dementia, only the posterior cingulate index, Mini-Mental State Examination (MMSE) score and apolipoprotein E4 genotype (ApoE4) exhibited significant independent effects in the univariable and multivariable models. When only the latter two clinical variables were included in the model, the AUC was 0.742 (95 % CI 0.646 – 0.838), but this increased to 0.804 (95 % CI 0.714 – 0.894, bootstrap p = 0.027) with the addition of the posterior cingulate index (AD-Conv score). Baseline clinical diagnosis of MCI showed 29.7 % of converters after 18 months. The observed probability of conversion in relation to baseline AD-Conv score was 75 % in the high probability group (sixtile 6), 34 % in the medium probability group (merged sixtiles 4 and 5), 20 % in the low probability group (sixtile 3) and 7.5 % in the very low probability group (merged sixtiles 1 and 2). In the validation population, the AD score reached an AUC of 0.948 (95 % CI 0.625 – 0.969) and the AD-Conv score reached 0.968 (95 % CI 0.908 – 1.000), with AD patients and MCI converters included in the highest probability categories.

Conclusion

Posterior cingulate hypometabolism, when combined in a multivariable model with age and gender as well as MMSE score and ApoE4 data, improved the determination of the likelihood of patients with MCI converting to AD dementia compared with clinical variables alone. The probabilistic model described here provides a new tool that may aid in the clinical diagnosis of AD and MCI conversion.
Literatur
1.
Zurück zum Zitat Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010;9:1118–27.PubMedCrossRef Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010;9:1118–27.PubMedCrossRef
2.
Zurück zum Zitat McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.PubMedCrossRefPubMedCentral McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.PubMedCrossRefPubMedCentral
3.
Zurück zum Zitat Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer Dement. 2011;7:270–9CrossRef Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer Dement. 2011;7:270–9CrossRef
4.
Zurück zum Zitat Sperling RA, Johnson KA. Dementia: new criteria but no new treatments. Lancet Neurol. 2012;11:4–5.PubMedCrossRef Sperling RA, Johnson KA. Dementia: new criteria but no new treatments. Lancet Neurol. 2012;11:4–5.PubMedCrossRef
5.
Zurück zum Zitat Bohnen NI, Djang DSW, Herholz K, Anzai Y, Minoshima S. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J Nucl Med. 2012;53:59–71.PubMedCrossRef Bohnen NI, Djang DSW, Herholz K, Anzai Y, Minoshima S. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J Nucl Med. 2012;53:59–71.PubMedCrossRef
6.
Zurück zum Zitat Landau S, Harvey D, Madison C, Reiman E, Foster N, Aisen P, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010;75:230–8.PubMedCrossRefPubMedCentral Landau S, Harvey D, Madison C, Reiman E, Foster N, Aisen P, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010;75:230–8.PubMedCrossRefPubMedCentral
7.
Zurück zum Zitat Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238–48.PubMed Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238–48.PubMed
8.
Zurück zum Zitat Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302–16.PubMedCrossRef Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302–16.PubMedCrossRef
9.
Zurück zum Zitat Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32:1207–18.PubMedCrossRefPubMedCentral Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32:1207–18.PubMedCrossRefPubMedCentral
10.
Zurück zum Zitat Chen K, Ayutyanont N, Langbaum JB, Langbaum J, Fleisher AS, Reschke C, et al. Characterizing Alzheimer’s disease using a hypometabolic convergence index. Neuroimage. 2011;56:52–60PubMedCrossRefPubMedCentral Chen K, Ayutyanont N, Langbaum JB, Langbaum J, Fleisher AS, Reschke C, et al. Characterizing Alzheimer’s disease using a hypometabolic convergence index. Neuroimage. 2011;56:52–60PubMedCrossRefPubMedCentral
11.
Zurück zum Zitat Shaffer JL, Petrella JR, Sheldon FC, Choudhury KR, Calhoun VD, Coleman RE, et al. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR Imaging, and PET biomarkers. Radiology. 2013;266:583–91PubMedCrossRef Shaffer JL, Petrella JR, Sheldon FC, Choudhury KR, Calhoun VD, Coleman RE, et al. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR Imaging, and PET biomarkers. Radiology. 2013;266:583–91PubMedCrossRef
12.
Zurück zum Zitat Caroli A, Prestia A, Chen K, Ayutyanont N, Landau SM, Madison CM, et al. Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J Nucl Med. 2012;53:592–600PubMedCrossRefPubMedCentral Caroli A, Prestia A, Chen K, Ayutyanont N, Landau SM, Madison CM, et al. Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J Nucl Med. 2012;53:592–600PubMedCrossRefPubMedCentral
13.
Zurück zum Zitat Herholz K, Westwood S, Haense C, Dunn G. Evaluation of a calibrated 18F-FDG PET score as a biomarker for progression in Alzheimer Disease and mild cognitive impairment. J Nucl Med. 2011;52:1218–26.PubMedCrossRef Herholz K, Westwood S, Haense C, Dunn G. Evaluation of a calibrated 18F-FDG PET score as a biomarker for progression in Alzheimer Disease and mild cognitive impairment. J Nucl Med. 2011;52:1218–26.PubMedCrossRef
14.
Zurück zum Zitat Cruchaga C, Fernández-Seara MA, Seijo-Martínez M, Samaranch L, Lorenzo E, Hinrichs A, et al. Cortical atrophy and language network reorganization associated with a novel progranulin mutation. Cerebral Cortex. 2009;19:1751–60.PubMedCrossRef Cruchaga C, Fernández-Seara MA, Seijo-Martínez M, Samaranch L, Lorenzo E, Hinrichs A, et al. Cortical atrophy and language network reorganization associated with a novel progranulin mutation. Cerebral Cortex. 2009;19:1751–60.PubMedCrossRef
15.
Zurück zum Zitat McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44.PubMedCrossRef McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44.PubMedCrossRef
16.
Zurück zum Zitat Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–94.PubMedCrossRef Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–94.PubMedCrossRef
17.
Zurück zum Zitat Wahlund L, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318–22.PubMedCrossRef Wahlund L, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318–22.PubMedCrossRef
18.
Zurück zum Zitat Pascual B, Prieto E, Arbizu J, Marti-Climent J, Olier J, Masdeu JC. Brain glucose metabolism in vascular white matter disease with dementia: differentiation from Alzheimer disease. Stroke. 2010;41:2889–93.PubMedCrossRef Pascual B, Prieto E, Arbizu J, Marti-Climent J, Olier J, Masdeu JC. Brain glucose metabolism in vascular white matter disease with dementia: differentiation from Alzheimer disease. Stroke. 2010;41:2889–93.PubMedCrossRef
19.
Zurück zum Zitat Friston KJ, Holmes AP, Worsley KJ, Poline J, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp. 1994;2:189–210.CrossRef Friston KJ, Holmes AP, Worsley KJ, Poline J, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp. 1994;2:189–210.CrossRef
20.
Zurück zum Zitat Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273–89.PubMedCrossRef Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273–89.PubMedCrossRef
21.
Zurück zum Zitat Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: Wiley; 2000. p. 91–142.CrossRef Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: Wiley; 2000. p. 91–142.CrossRef
22.
Zurück zum Zitat Fox J. Applied regression analysis and generalized linear models. 2nd ed. Thousand Oaks: Sage; 2008. p. 587–606. Fox J. Applied regression analysis and generalized linear models. 2nd ed. Thousand Oaks: Sage; 2008. p. 587–606.
23.
24.
Zurück zum Zitat Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2012;8:S1–68.PubMedCrossRefPubMedCentral Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2012;8:S1–68.PubMedCrossRefPubMedCentral
25.
Zurück zum Zitat Drzezga A, Grimmer T, Henriksen G, Mühlau M, Perneczky R, Miederer I, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology. 2009;72:1487–94.PubMedCrossRef Drzezga A, Grimmer T, Henriksen G, Mühlau M, Perneczky R, Miederer I, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology. 2009;72:1487–94.PubMedCrossRef
26.
Zurück zum Zitat Pievani M, Galluzzi S, Thompson PM, Rasser PE, Bonetti M, Frisoni GB. APOE4 is associated with greater atrophy of the hippocampal formation in Alzheimer’s disease. Neuroimage. 2011;55:909–19.PubMedCrossRef Pievani M, Galluzzi S, Thompson PM, Rasser PE, Bonetti M, Frisoni GB. APOE4 is associated with greater atrophy of the hippocampal formation in Alzheimer’s disease. Neuroimage. 2011;55:909–19.PubMedCrossRef
27.
Zurück zum Zitat Chen K, Ayutyanont N, Langbaum JB, Langbaum J, Fleisher AS, Reschke C, et al. Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E ε4 gene dose in cognitively normal adults: a cross-validation study using voxel-based multi-modal partial least squares. Neuroimage 2012;60:2316–22PubMedCrossRefPubMedCentral Chen K, Ayutyanont N, Langbaum JB, Langbaum J, Fleisher AS, Reschke C, et al. Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E ε4 gene dose in cognitively normal adults: a cross-validation study using voxel-based multi-modal partial least squares. Neuroimage 2012;60:2316–22PubMedCrossRefPubMedCentral
28.
Zurück zum Zitat Reiman EM, Uecker A, Caselli RJ, Lewis S, Bandy D, De Leon MJ, et al. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer’s disease. Ann Neurol. 1998;44:288–91.PubMedCrossRef Reiman EM, Uecker A, Caselli RJ, Lewis S, Bandy D, De Leon MJ, et al. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer’s disease. Ann Neurol. 1998;44:288–91.PubMedCrossRef
29.
Zurück zum Zitat Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and 18F-FDG PET. J Nucl Med. 2005;46:1625–32.PubMed Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and 18F-FDG PET. J Nucl Med. 2005;46:1625–32.PubMed
30.
Zurück zum Zitat Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology. 2004;63:2332–40.PubMedCrossRef Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology. 2004;63:2332–40.PubMedCrossRef
31.
Zurück zum Zitat Schuff N, Woerner N, Boreta L, Kornfield T, Shaw L, Trojanowski J, et al. MRI of hippocampal volume loss in early Alzheimer’s disease in relation to ApoE genotype and biomarkers. Brain. 2009;132:1067–77.PubMedCrossRefPubMedCentral Schuff N, Woerner N, Boreta L, Kornfield T, Shaw L, Trojanowski J, et al. MRI of hippocampal volume loss in early Alzheimer’s disease in relation to ApoE genotype and biomarkers. Brain. 2009;132:1067–77.PubMedCrossRefPubMedCentral
32.
Zurück zum Zitat Bouwman FH, Verwey NA, Klein M, Kok A, Blankenstein M, Sluimer J, et al. New research criteria for the diagnosis of Alzheimer’s disease applied in a memory clinic population. Dement Geriatr Cogn Disord. 2010;30:1–7.PubMedCrossRef Bouwman FH, Verwey NA, Klein M, Kok A, Blankenstein M, Sluimer J, et al. New research criteria for the diagnosis of Alzheimer’s disease applied in a memory clinic population. Dement Geriatr Cogn Disord. 2010;30:1–7.PubMedCrossRef
33.
Zurück zum Zitat Schoonenboom NSM, van der Flier WM, Blankenstein MA, Bouwman FH, Van Kamp GJ, Barkhof F, et al. CSF and MRI markers independently contribute to the diagnosis of Alzheimer’s disease. Neurobiol Aging. 2008;29:669–75.PubMedCrossRef Schoonenboom NSM, van der Flier WM, Blankenstein MA, Bouwman FH, Van Kamp GJ, Barkhof F, et al. CSF and MRI markers independently contribute to the diagnosis of Alzheimer’s disease. Neurobiol Aging. 2008;29:669–75.PubMedCrossRef
34.
Zurück zum Zitat Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol. 1997;42:85–94.PubMedCrossRef Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol. 1997;42:85–94.PubMedCrossRef
35.
Zurück zum Zitat Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486–510.PubMedCrossRef Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486–510.PubMedCrossRef
36.
Zurück zum Zitat Jack Jr CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9:119–28.PubMedCrossRefPubMedCentral Jack Jr CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9:119–28.PubMedCrossRefPubMedCentral
37.
Zurück zum Zitat Pagani M, Dessi B, Morbelli S, Brugnolo A, Salmaso D, Piccini A, et al. MCI patients declining and not-declining at mid-term follow-up: FDG-PET findings. Curr Alzheimer Res. 2010;7:287–94.PubMedCrossRef Pagani M, Dessi B, Morbelli S, Brugnolo A, Salmaso D, Piccini A, et al. MCI patients declining and not-declining at mid-term follow-up: FDG-PET findings. Curr Alzheimer Res. 2010;7:287–94.PubMedCrossRef
38.
Zurück zum Zitat Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30:1104–13.PubMedCrossRef Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30:1104–13.PubMedCrossRef
39.
Zurück zum Zitat Yakushev I, Schreckenberger M, Müller MJ, Schermuly I, Cumming P, Stoeter P, et al. Functional implications of hippocampal degeneration in early Alzheimer’s disease: a combined DTI and PET study. Eur J Nucl Med Mol Imaging. 2011;38:2219–27.PubMedCrossRef Yakushev I, Schreckenberger M, Müller MJ, Schermuly I, Cumming P, Stoeter P, et al. Functional implications of hippocampal degeneration in early Alzheimer’s disease: a combined DTI and PET study. Eur J Nucl Med Mol Imaging. 2011;38:2219–27.PubMedCrossRef
40.
Zurück zum Zitat Morbelli S, Drzezga A, Perneczky R, Frisoni GB, Caroli A, van Berckel BN, et al. Resting metabolic connectivity in prodromal Alzheimer’s disease. A European Alzheimer Disease Consortium (EADC) project. Neurobiol Aging. 2012;33:2533–50PubMedCrossRef Morbelli S, Drzezga A, Perneczky R, Frisoni GB, Caroli A, van Berckel BN, et al. Resting metabolic connectivity in prodromal Alzheimer’s disease. A European Alzheimer Disease Consortium (EADC) project. Neurobiol Aging. 2012;33:2533–50PubMedCrossRef
Metadaten
Titel
Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer’s disease dementia
verfasst von
Javier Arbizu
E. Prieto
P. Martínez-Lage
J. M. Martí-Climent
M. García-Granero
I. Lamet
P. Pastor
M. Riverol
M. T. Gómez-Isla
I. Peñuelas
J. A. Richter
M. W. Weiner
for the Alzheimer’s Disease Neuroimaging Initiative
Publikationsdatum
01.09.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2013
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-013-2458-z

Weitere Artikel der Ausgabe 9/2013

European Journal of Nuclear Medicine and Molecular Imaging 9/2013 Zur Ausgabe